This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

SO270

Clinical features of interictal dysphoric disorder in drug-resistant epilepsy

CLINICAL FEATURES OF INTERICTAL DYSPHORIC DISORDER IN DRUG-RESISTANT EPILEPSY

Interictal dysphoric disorder was identified in one-third of patients with drug-resistant epilepsy and was associated with mood and anxiety disorders, lower vocabulary scores, and poorer quality of life across all domains.

The aim was to investigate the possible associations of interictal dysphoric disorder (IDD) with psychiatric disorders, cognitive function, and quality of life in patients with drug-resistant epilepsy (DRE). This retrospective study included 281 adult patients diagnosed with DRE at the Hospital Clinic Epilepsy Unit between 2008 and 2017; Axis I psychiatric disorders were assessed using the Structured Clinical Interview for DSM-IV (SCID-IV), cognitive function using the WAIS III, WMS III, Trail Making Test A and B, Rey Auditory Verbal Learning Test, and Boston Naming Test, and quality of life (QoL) using the Spanish version of the Quality of Life in Epilepsy Inventory-31 (QOLIE-31). A diagnosis of IDD required the presence of at least three of eight symptoms: depressed mood, lack of energy, pain, insomnia, fear, anxiety, irritability, and euphoric mood. Student's t-test was used for continuous variables and the chi-square test for categorical variables, with the significance level set at p < 0.05, taking multiple comparisons into account. Of the 281 patients, 97 (34.3%) were diagnosed with IDD, while 184 (65.7%) did not meet the criteria. The mean age of the IDD group was 39.2 ± 12.26 years, and the majority were women (59.1%); 70 of the 97 patients diagnosed with IDD also had a psychiatric disorder according to the SCID-IV assessment. IDD was significantly associated with mood and anxiety disorders (p < 0.05), but no significant associations were found with other psychiatric disorders. In terms of cognition, IDD was significantly associated only with lower scores on the WAIS III Vocabulary subtest (p < 0.05); no significant associations were found with other neuropsychological measures. The presence of IDD was significantly associated with lower scores across all QOLIE-31 domains (p < 0.05), indicating poorer quality of life; the authors concluded that IDD is clinically important across several key domains in drug-resistant epilepsy.

All WCP 2026 summaries